Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen, Vir Enter COVID-19 Antibody Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Biogen, Vir Enter COVID-19 Antibody Alliance

Biogen will provide cell line development, process development and clinical manufacturing for Vir's monoclonal antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen and Vir Biotechnology have entered an antibody development and manufacturing agreement to develop Vir’s monoclonal antibodies against coronavirus.

Under the agreement, Biogen will provide cell line development, process development and clinical manufacturing for Vir’s monoclonal antibodies. Vir has discovered antibodies that bind to the novel coronavirus, and is testing whether they can treat or prevent the infection.

“Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies,” said George Scangos, Vir’s CEO.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics